Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.
MED2005, our lead product, is a topical glyceryl trinitrate (GTN) gel which has the potential to be a highly differentiated therapy, especially for mild to moderate ED.
| Concept | Development | Commercialisation | ||
|---|---|---|---|---|
| MED2005 | ||||
| Description: Topical gel for erectile dysfunction |  |
|||
| Status: First Phase 3 study underway with headline data by end of 2019. Out-licensing discussions ongoing | ||||
| TPR100 | ||||
| Description: Topical diclofenac pain relief gel | |
|||
| Status: Regulatory dossier submitted in the UK. UK licence partner addressing queries with support from Futura. Licensing discussions for further territories ongoing. | ||||
| Concept | Development | Commercialisation | ||
|---|---|---|---|---|
| CBD100 | ||||
| Description: Topical Cannabidiol formulation | |
|||
| Status: Joint venture collaboration. Early development stage to explore a number of disease states including pain relief. | ||||
| CSD500 | ||||
| Description: Condom containing an erectogenic gel | ||||
| Status: Approved in the EU, 24 month shelf life | ||||
| TIB200 | ||||
| Description: Topical ibuprofen pain relief gel | |
|||
| Status: Out-licencing discussions ongoing | ||||